IP Library › Granted Patent US 9,732,060
Granted Patent B2
US 9,732,060 · App. 14/897,836 · Granted Aug 15, 2017

Aminotriazine derivative and pharmaceutical composition comprising the same

Inventor: Hiroyuki Kai (Osaka, JP)
Assignee: SHIONOGI & CO., LTD.
C07D401/12C07D405/14C07D409/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,060
App. No.
14/897,836
Granted
Aug 15, 2017
Kind
B2
Abstract

The present invention provides novel compounds having a P2X 3 and/or P2X 2/3 receptor antagonistic activity. A compound of Formula (I): wherein R a and R b , and R d and R e are taken together to form oxo or the like; R 4a and R 4b are hydrogen or the like; n is 1 or the like; R 2 is aryl or the like; s and s′ is 0 or the like; R 9 and R 9 ′ are halogen or the like; R 20a and R 20b are hydrogen, alkyl or the like; u is 1 to 4; R 13 is hydrogen or the like, or its pharmaceutically acceptable salt.

Claims (12)

1. A compound of formula:

or its pharmaceutically acceptable salt.

2. A pharmaceutical composition comprising the compound according to claim 1 , or its pharmaceutically acceptable salt, and further comprising a pharmaceutical additive.

3. The pharmaceutical composition according to claim 2 , wherein the composition has a P2X 3 and/or P2X 2/3 receptor antagonistic activity.

4. The compound according to claim 1 , chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.

5. The compound according to claim 1 , chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.

6. The compound according to claim 1 , chosen from a compound of the following formula:

or its pharmaceutically acceptable salt.

7. A pharmaceutical composition comprising the compound according to any one of claims 4 , 5 and 6 , or its pharmaceutically acceptable salt, and further comprising a pharmaceutical additive.

8. The pharmaceutical composition according to claim 7 , wherein the composition has a P2X 3 and/or P2X 2/3 receptor antagonistic activity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2015
From: KAI, HIROYUKI
To: SHIONOGI & CO., LTD.
Reel/Frame 037307/0737 →
Priority Claims (1)
JP 2013-125134 · Jun 14, 2013 · national
Continuity (1)
Related Publication 20160115151A1 · Apr 28, 2016